Brief: Polyphor's Balixafortide Shows Efficacy In COVID-19 Preclinical Trials

Spexis AG

01/06/2021 06:32

June 1 (Reuters) - POLYPHOR AG  POLN.S :
    * BALIXAFORTIDE DEMONSTRATES CONSISTENT DUAL ACTION
ANTI-VIRAL AND
ANTI-INFLAMMATORY ACTIVITY IN COVID-19 PRECLINICAL TRIALS
    * RESULTS FROM THIS PHASE III TRIAL ARE EXPECTED FOR
OBJECTIVE
RESPONSE RATE (ORR) END OF Q2 AND FOR PROGRESSION FREE SURVIVAL
(PFS) IN Q4 2021

Source text for Eikon:  ID:nEQ6qpr41a 
Further company coverage:  POLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))